Jefferies Group’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-25,100
Closed -$2.81M 1643
2020
Q4
$2.81M Sell
25,100
-46,200
-65% -$4.87M 0.02% 604
2020
Q3
$6.61M Buy
71,300
+20,100
+39% +$1.55M 0.07% 228
2020
Q2
$3.99K Sell
51,200
-20,700
-29% -$1.4M 0.05% 329
2020
Q1
$4.21M Sell
71,900
-1,000
-1% -$64.4K 0.05% 376
2019
Q4
$5.84M Buy
72,900
+36,900
+103% +$2.76M 0.05% 452
2019
Q3
$2.65M Hold
36,000
0.02% 907
2019
Q2
$3.4M Buy
+36,000
New +$2.97M 0.02% 663

Other funds holding BPMC

Jefferies Group's BPMC Position: Q1 2021 in Review

Jefferies Group sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 14,000 shares — an estimated $1.57M sold.

Jefferies Group first reported a position in BPMC in Q2 2018 and held it in 7 quarters. The position peaked at $2.43M in Q4 2019. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Jefferies Group reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Jefferies Group sold 14,000 Blueprint Medicines shares in Q1 2021, an estimated $1.57M.
  • Jefferies Group first reported a position in Blueprint Medicines in Q2 2018 and held it in 7 quarters.
  • Jefferies Group's Blueprint Medicines position peaked at $2.43M in Q4 2019.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.